ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2483

Major Secular Trends of Patient Characteristics and Inclusion Criteria in RA Clinical Trials

Andreas Kerschbaumer1, Bruno Bierbaumer2, Josef S. Smolen3 and Daniel Aletaha4, 1Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Independent, Munich, Germany, 3Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 4Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: clinical trials, meta-analysis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatoid arthritis (RA) is among the most intensively studied chronic inflammatory musculoskeletal diseases. Over the past two decades numerous new compounds have been tested in RA. Although the results from any new clinical trial in RA is usually interpreted in the context of existing data from previous trials, it is not clear whether trial populations are necessarily historically comparable. We investigated secular trends in characteristics of patient populations enrolled in RA clinical trials and inclusion criteria as possible influencing factors.

Methods:

We performed a systematic literature review of randomized, controlled, double-blind trials, investigating biological therapies in RA. Reports were identified using PUBMED, EMBASE and the Cochrane Library. Populations were stratified into conventional disease modifying anti-rheumatic drug (DMARD) naïve, DMARD inadequate responders (IR), and biological DMARD IR. The following variables at baseline were extracted from reports: swollen and tender joint counts (SJC, TJC), pain, patient and evaluator global (PGA, EGA), acute phase measures (erythrocyte sedimentation rate, ESR and C-reactive protein, CRP), as well as the Health Assessment Questionnaire Disability Index (HAQ). In addition, we obtained the year of publication and the inclusion criteria (IC) of each trial. We then performed a mixed model meta-regression of year of publication on each of the mentioned variables and IC.

Results:

Out of 697 abstracts selected for screening, 73 studies were chosen as relevant; 3 studies with mixed populations were excluded, resulting in 70 studies included for analysis. Table 1 shows the medians and quartiles for the baseline characteristics. Meta-regression showed a significant decrease of SJC (β=-0.415;p<.001), TJC (β=-0.378;p<.001), and CRP (β=-0.123;p<.001) over the years (figure 1); for all other core set measures, there was no trend or significance. IC showed similar trends over time for SJC (β=-0.154;p<.001), TJC (β=-0.243;p<.001), and CRP (β=-0.065;p<.001). Furthermore, there were significant linear associations of IC with SJC (β=1.33;p<.001), TJC (β=1.14;p<.001) and CRP (β=1.16;p<.001) at baseline.

Conclusion:

There is a progressive drift towards lower number of swollen and tender joints and lower CRP-levels at trial entry of time, which is at least partly related to a similar trend in inclusion criteria for RA. The constancy of patient-reported outcomes suggests that the baseline activity is still perceived as similarly high. Differences in overall baseline inflammatory activity may pose a challenge for comparing newer with older trial results.

DMARD NAIVE

bDMARD IR

csDMARD IR

No of trials (n)

13

9

48

No of study arms (n)

39

25

180

No of patients (n)

8894

4584

23752

Year of publication (YYYY)

2014 (2009–2016)

2013 (2008–2016)

2008 (2003–2012)

CRP (mg/dL)

2.59 (2.27–3.26)

2.1 (1.08–3.11)

2.08 (1.67–3)

ESR (mm/h)

49.4 (42–52.8)

46.85 (39.2–48.2)

45.95 (40.2–49.9)

Swollen Joints (0-66)

16.65 (16–20.3)

17.1 (16.2–19)

17.95 (15.59–20.4)

Tender Joints (0-68)

28.05 (25.5–31)

28.75 (25.6–31.2)

28.1 (25.88–31.7)

Patient global assessment (0-100)

63.9 (61.8–66)

66.5 (63–69.7)

61 (58–65)

Evaluator global assessment (0-100)

63.6 (62–65.6)

66.45 (62–67)

62.05 (59.7–65)

Patients pain assessment (0-100)

62.5 (60.9–64.6)

65 (62–69)

60.29 (56.66–65)

Health assessment questionnaire (0-3)

1.54 (1.50–1.63)

1.7 (1.60–1.74)

1.51 (1.41–1.66)

 

 


Disclosure: A. Kerschbaumer, Bristol-Myers-Squibb and Pfizer, 9; B. Bierbaumer, None; J. S. Smolen, Abbvie, Astra-Zeneca - to Institution, 2,Abbvie, Chugai, Gilead, ILTOO, Janssen, Lilly, MSD, Novartis-Sandoz, Pfizer, Samsung, Sanofi, 5,Abbvie, Celgene, Chugai, Janssen, Lilly, MSD, Pfizer, Samsung, Sandoz, UCB, 9; D. Aletaha, AbbVie, Merck Sharp and Dohme, Roche, 2,AbbVie, Janssen, Lilly, Novartis, Pfizer, Roche, 5,AbbVie, Janssen, Lilly, Novartis, Pfizer, Roche, Bristol-Myers Squibb, Celgene, Merck, Sharp and Dohme, UCB, 9.

To cite this abstract in AMA style:

Kerschbaumer A, Bierbaumer B, Smolen JS, Aletaha D. Major Secular Trends of Patient Characteristics and Inclusion Criteria in RA Clinical Trials [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/major-secular-trends-of-patient-characteristics-and-inclusion-criteria-in-ra-clinical-trials/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/major-secular-trends-of-patient-characteristics-and-inclusion-criteria-in-ra-clinical-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology